9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

Clinical trial NCT06823427 · RECRUITING

Trial details

NCT number: NCT06823427
Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Urothelial Carcinoma Urothelial Carcinoma Bladder Urothelial Carcinoma Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter

Start date: 2025-01-17
Primary completion: 2026-06-01
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.